NEW YORK, NY--(Marketwire - Oct 13, 2011) - Daxor Corporation (NYSE Amex: [ DXR ]), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Schnitzler Cardiovascular Consultants PLLC (SCC). This will provide SCC with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of conditions. BVA allows for more accurate diagnosis of volume status. This provides another tool for complex management of heart failure, renal failure and other complex problems associated with volume status questions.

SCC will be participating in a multi-center clinical trial (TEAM-HF) which will test whether incorporation of blood volume assessments into treatment decisions can improve the care and outcomes of patients with heart failure. Dr. Schnitzler, President of the SCC, will serve as the local Principal Investigator, and will be joined by Victoria Paparelli MSN, RN, CCNS-AC and Andrew De Leon to conduct the study at SCC. The objective of the interventional TEAM-HF Study is to determine whether correcting any identified blood volume abnormalities in heart failure patients leads to decreased hospitalization and mortality, and an improvement in exercise capacity and quality of life.

This trial will enroll 300 heart failure patients from multiple medical centers. Dr. Stuart Katz, the Director of the Heart Failure Program at the New York University Langone Medical Center, will serve as the National Principal Investigator for this study.

SCC is located in San Antonio, Texas and was founded in 1977 by Dr. Robert N. Schnitzler. Dr. Schnitzler has dedicated his life to provide superior medical care to Texans for over 30 years. Since the beginning of his career Dr. Schnitzler has been dedicated to research that advances the field of cardiovascular hemodynamic and cardiac electrophysiology. SCC has a 16,000 patient database with 4 physicians having the ability to treat acute myocardial infarction, atrial fibrillation heart failure, acute coronary syndrome, arrhythmias, coronary artery disease, high Cholesterol, hypertension and among many others.

Dr. Schnitzler said, "The ability to make a Blood Volume Analysis precisely is one of the most important recent developments in treating heart failure. We look forward to being part of the TEAM-HF study that documents the benefits of being able to treat patients in a more precise manner."

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at [ www.Daxor.com ].